Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director.
MISSION Therapeutics
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.
Telephone: +44 (0)1223 607 340
Address :
The Glenn Berge Building Building 940 Babraham Research Campus, Babraham Cambridge
Post Code: CB22 3FH
Country: United Kingdom
Website: http://www.missiontherapeutics.com/
Membership Type: Corporate 21-50
MISSION Therapeutics holds and will maintain world-leadership in the DNA damage response (DDR) and associated molecular pathways. MISSION Therapeutics will use its knowledge and proven expertise in targeting these pathways for small-molecule drug discovery to develop new therapeutic agents with wide market potential. These drugs will mainly target "Achilles heels" of cancer by exploiting the concept of synthetic-lethality. The Company is building a pipeline of novel targets within the ubiquitin pathways controlling DDR and are particularly focussed on deubiquitylating proteases.
MISSION Therapeutics was founded by Professor Steve Jackson, a world expert on the DNA damage response. Steve is Senior Group Leader and Head of Cancer Research UK Laboratories in the Gurdon Institute, Cambridge University and is the University's Frederick James Quick Professor of Biology. For information on his research, see http://www.gurdon.cam.ac.uk/~jacksonlab/
There are no Products & Services to display
25-03-2021
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect.
06-08-2020
Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.
08-03-2018
Mission Therapeutics is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.
15-11-2017
Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering a presentation today at the Parkinson’s Disease Therapeutics Conference in New York City.
30-10-2017
There are no events to display
16/04/2021
Senior / Principal Scientist, CNS (Translational Science) – Cambridge, UK
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of...
Location: Within 10 miles of Cambridge
Salary Range:
15/04/2021
Head of Clinical Pharmacology & Pharmacometrics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney...
Location: Cambridge
Salary Range:
£60,000+
No Blog articles found
